Home › Trial NCT07570966
Study of ERW316 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
- Trial IDNCT07570966
- StatusWithdrawn
- PhasePhase 1/2
- Study typeInterventional
- SponsorNovartis Pharmaceuticals
- Enrollment—
- Start date2026-06-30
- ConditionsAdvanced HR+/HER2- Breast Cancer · Advanced CCNE1-amplified Solid Tumors · Metastatic Castration-resistant Prostate Cancer (mCRPC)
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.